This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | MicrobiomeTrials
← Back to trials NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-23Est. Completion: 2028-10-31
Enrollment target: 380 participantsLocations City of Hope National Medical Center, Duarte, California, United States City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States Yale University, New Haven, Connecticut, United States MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States Emory University Hospital Midtown, Atlanta, Georgia, United States Novant Health Cancer Institute, Charlotte, North Carolina, United States Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States TriHealth Cancer and Blood Institute, Cincinnati, Ohio, United States West Virginia University, Morgantown, West Virginia, United States St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China Other microbiome trials you might be interested in Multiple Myeloma Plasma Cell Leukemia
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high r…
Salt Lake City, United States Est. completion Nov 2026
Relapsed/Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evalua…
Wuhu, China Est. completion Oct 20, 2026
The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China
The First Affilliated Hospital of Kunming Medical University, Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS, Hangzhou, Zhejiang, China
Nanfang Hospital, Southern Medical University, Guangzhou, China
Qilu Hospital of Shandong University, Jinan, China
The First Affiliate Hospital of Guangxi Medical University, Nanning, China
Zhongshan Hospital Fudan University, Shanghai, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
The First Affiliated Hospital of Soochow University, Suzhou, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia
Fakultni nemocnice Ostrava, Ostrava, Czechia
Aarhus Universitetshospital, Aarhus, Denmark
Sygehus Lillebælt, Vejle;Hæmatologisk Forskningsenhed, HKFE, Vejle, Denmark
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
Vivantes Klinikum Am Urban Klinik für Innere Medizin Hämatologie und Onkologie, Berlin, Germany
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
Marien-Hospital Klinik f.Hämatologie Onkologie u.Palliativmedizin, Düsseldorf, Germany
Universitätsklinikum Frankfurt, Frankfurt, Germany
Universitätsmedizin Greifswald, Greifswald, Germany
UKSH, Campus Kiel, Kiel, Germany
Evangelismos General Hospital of Athens, Athens, Greece
Alexandras General Hospital of Athens, Athens, Greece
Anticancer Hospital of Thessaloniki " Theagenio", Thessaloniki, Greece
Rambam Health Care Campus, Haifa, Israel
Hadassah Ein Karem Hospital, Jerusalem, Israel
Chaim Sheba Medical Center, Ramat Gan, Israel
Ichilov Sourasky Medical Center, Tel Aviv, Israel
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori", Meldola, Emilia-Romagna, Italy
Asst Papa Giovanni Xxiii, Bergamo, Lombardy, Italy
Istituto Clinico Humanitas, Rozzano, Lombardy, Italy
Toyohashi Municipal Hospital, Toyohashi, Aichi-ken, Japan
Nagoya City University Hospital, Aichi, Japan
Matsuyama Red Cross Hospital, Ehime, Japan
Gunma University Hospital, Gunma, Japan
Hyogo Medical University Hospital, Hyōgo, Japan
University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan
Iwate Medical University Hospital, Numakunai, Japan
National Hospital Organization Okayama Medical Center, Okayama, Japan
Osaka University Hospital, Osaka, Japan
Dokkyo Medical University Saitama Medical Center, Saitama, Japan
Japanese Red Cross Medical Center, Shibuya-ku, Japan
The Cancer Institute Hospital of JFCR, Tokyo, Japan
Yamagata University Hospital, Yamagata, Japan
SP ZOZ Szpital Uniwersytecki w Krakowie-Jakubowskiego 2;Oddzial Kliniczny Hematologii, Krakow, Lesser Poland Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne, Gda?sk, Poland
Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy, Warsaw, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroc?aw, Poland
Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Seoul St Mary's Hospital, Seoul, South Korea
Hospital Costa del Sol, Marbella, Malaga, Spain
Clinica Universitaria de Navarra, Pamplona, Navarre, Spain
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
Hospital General Universitario Gregorio Marañon, Madrid, Spain
Hospital Clinico Universitario de Salamanca, Salamanca, Spain